Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Ukendt tidspunkt for indsættelsestidspunkt for apopleksi med reperfusion uden avanceret billeddannelse (UTOPIA)

Intravenøs Tenekteplase til Akut Iskæmisk Apopleksi med Ukendt Symptomstartstidspunkt Under Uden Kontrastmiddel CT-selektion: Et Multicenter, Prospektivt, Randomiseret, Åbent, Blindet Endpunktsforsøg

The benefit of intravenous tenecteplase for acute ischemic stroke with unknown time of onset, e.g. wake-up stroke, remains uncertain. This randomized study aims to assess the efficacy and safety of intravenous tenecteplase following non-contrast CT screening for acute ischemic stroke with unknown time of onset.

Studieoversigt

Detaljeret beskrivelse

UTOPIA is an investigator-initiated, multicenter, prospective, randomized, open-label, blinded endpoint (PROBE) trial that aims to assess the efficacy and safety of intravenous tenecteplase for acute ischemic stroke with unknown time of onset, selected by non-contrast CT. The primary outcome is excellent outcome, as defined by a score of 0 or 1 on modified Rankin Scale (mRS) at 90 days.

Participants randomized to the intervention group will receive intravenous tenecteplase at 0.25 mg/kg with a maximum dose of 25 mg and standard medical treatment, and those randomized to the control group will receive standard medical treatment only, without intravenous thrombolysis.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

352

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Fujian
      • Xiamen, Fujian, Kina, 361004
        • Ikke rekrutterer endnu
        • Zhongshan Hospital of Xiamen University
        • Kontakt:
          • Xingyu Chen
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510620
        • Ikke rekrutterer endnu
        • Guangzhou Twelfth People's Hospital
        • Kontakt:
          • Jianwu Dai
    • Guangxi
      • Baise City, Guangxi, Kina, 533000
        • Ikke rekrutterer endnu
        • Baise People's Hospital
        • Kontakt:
          • Dengxing Li
      • Chongzuo, Guangxi, Kina, 532200
        • Rekruttering
        • The People's Hospital of Chongzuo
        • Kontakt:
          • Jianyi Huang
      • Guigang, Guangxi, Kina, 537121
        • Ikke rekrutterer endnu
        • People's Hospital of Qintang District, Guigang City
        • Kontakt:
          • Jixin Lu
      • Guigang, Guangxi, Kina, 537200
        • Ikke rekrutterer endnu
        • Guiping People's Hospital
        • Kontakt:
          • Peiquan Yang
      • Laibin, Guangxi, Kina, 545900
        • Ikke rekrutterer endnu
        • Wuxuan County People's Hospital
        • Kontakt:
          • Yu Huang
      • Liuzhou, Guangxi, Kina, 545007
        • Ikke rekrutterer endnu
        • Liuzhou Workers' Hospital
        • Kontakt:
          • Liya Pan
      • Nanning, Guangxi, Kina, 530021
        • Ikke rekrutterer endnu
        • The First Affiliated Hospital of Guangxi Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Yuan Wu, MD, PhD
      • Nanning, Guangxi, Kina, 530200
        • Ikke rekrutterer endnu
        • Nanning Yongning District People's Hospital
        • Kontakt:
          • Wuqiao Liang
        • Kontakt:
          • Qihai Zhou
      • Nanning, Guangxi, Kina, 530219
        • Ikke rekrutterer endnu
        • Guangxi Medical University Kaiyuan Langdong Hospital
        • Kontakt:
          • Kai Chen
      • Nanning, Guangxi, Kina, 530409
        • Ikke rekrutterer endnu
        • No.9 People's Hospital of Nanning
        • Kontakt:
          • Jun Qu
      • Qinzhou, Guangxi, Kina, 535000
        • Ikke rekrutterer endnu
        • The Second People's Hospital of Qinzhou
        • Kontakt:
          • Caixia Xuan
    • Shaanxi
      • Yulin, Shaanxi, Kina, 718100
        • Ikke rekrutterer endnu
        • Mizhi County Hospital
        • Kontakt:
          • Tao Zhang
      • Yulin, Shaanxi, Kina, 718600
        • Ikke rekrutterer endnu
        • Dingbian County People's Hospital
        • Kontakt:
          • Gaiyan Qu

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Age ≥ 18 years old.
  2. Clinical diagnosis of acute ischemic stroke.
  3. Unknown time of stroke onset (e.g., stroke symptom recognized on awakening) but last-known normal time >4.5 hours.
  4. Time from stroke symptom recognition (e.g., awakening) to randomization within 3 hours.
  5. National Institutes of Health Stroke Scale (NIHSS) score of 6-25 (both inclusive).
  6. Pre-stroke modified Rankin Scale (mRS) score of 0-1.
  7. Written informed consent from patients or their legally authorized representatives.

Exclusion Criteria:

  1. Intracranial hemorrhage confirmed by skull CT, or history of intracranial hemorrhage.
  2. Planned endovascular treatment.
  3. Rapid neurological improvement with NIHSS <6 at randomization.
  4. Allergy to tenecteplase.
  5. Use of vitamin K antagonist with INR >1.7, use of heparin or low molecular heparin in the past 24 hours, or use of direct oral anticoagulants in the past 48 hours.
  6. Hypodensity on non-contrast CT >1/3 middle cerebral artery territory.
  7. Severe traumatic brain injury or other major trauma in the past 3 months.
  8. Intracranial neoplasm, arteriovenous malformation, or aneurysm (≥10mm).
  9. Intracranial surgery, intraspinal surgery, or other major surgery in the past 3 months.
  10. Gastrointestinal or urinary tract hemorrhage in the past 3 weeks.
  11. Active internal bleeding.
  12. Aortic dissection.
  13. Infective endocarditis.
  14. Platelet count <100×10^9/L.
  15. Women who are pregnant or breastfeeding.
  16. Blood glucose <50 or >400 mg/dL (<2.78 or >22.2 mmol/L).
  17. Systolic blood presure >185 mmHg or diastolic blood presure >110 mmHg refractory to treatment.
  18. Life expectancy <3 months.
  19. Participating in other trials.
  20. Any condition that, in the judgment of the investigator, makes the patient unsuitable for this study or where this study may impose a significant risk to the patient (e.g., inability to understand and/or comply with study procedures and/or follow-up due to psychiatric disorders, cognitive or emotional impairment).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Andet: Control group

Standard Medical Treatment

Standard medical treatment should adhere to clinical guidelines and usual care at site, including antiplatelet therapy, anticoagulant therapy, lipid-lowering therapy, antihypertensive drugs, etc., as determined by the local investigators.

Eksperimentel: Tenecteplase group

Intravenous tenecteplase thrombolysis

Standard medical treatment should adhere to clinical guidelines and usual care at site, including antiplatelet therapy, anticoagulant therapy, lipid-lowering therapy, antihypertensive drugs, etc., as determined by the local investigators.

Tenecteplase is administered as a single intravenous bolus at a dose of 0.25 mg/kg, with a maximum of 25 mg, administered as soon as possible after the randomization.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Excellent outcome
Tidsramme: 90 (±14) days

The proportion of modified Rankin Scale (mRS) score of 0-1 at 90 days

90 (±14) days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Level of disability
Tidsramme: 90 (±14) days

Ordinal shift analysis of the mRS with 5-6 merged at 90 days.

90 (±14) days
Functional independence
Tidsramme: 90 (±14) days

The proportion of mRS score of 0-2 at 90 days.

90 (±14) days
Early neurological improvement
Tidsramme: 24 (±12) hours

The proportion of NIHSS 0-1 or ≥4 points reduction at 24 (±12) hours.

24 (±12) hours
Change in stroke severity
Tidsramme: 7 (±1) days or at discharge

The change of NIHSS score from baseline to 7 days or at discharge (whichever comes first)

7 (±1) days or at discharge
Quality of life measured by EQ-5D-5L
Tidsramme: 90 (±14) days

EQ-5D-5L scale score at 90 days.

90 (±14) days

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Symptomatic intracranial hemorrhage
Tidsramme: 24 (±12) hours

Incidence of symptomatic intracranial hemorrhage within 36 hours from randomization (Heidelberg criteria)

24 (±12) hours
Any intracranial hemorrhage
Tidsramme: 24 (±12) hours

Incidence of any intracranial hemorrhage within 36 hours from randomization (Heidelberg classification)

24 (±12) hours
Extracranial bleeding
Tidsramme: 24 (±12) hours

Incidence of moderate-to-severe extracranial bleeding (GUSTO criteria) within 36 hours from randomization

24 (±12) hours
Mortality
Tidsramme: 90 days

All cause death within 90 days.

90 days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Yuan Wu, MD, PhD, First Affiliated Hospital of Guangxi Medical University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

24. september 2026

Primær færdiggørelse (Anslået)

1. december 2028

Studieafslutning (Anslået)

1. december 2028

Datoer for studieregistrering

Først indsendt

13. marts 2026

Først indsendt, der opfyldte QC-kriterier

13. marts 2026

Først opslået (Faktiske)

17. marts 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

29. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Data supporting the findings of the study are available on reasonable request after approval of a proposal from the principal investigator.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner